Form 4: ImmunityBio Director Granted Significant Stock Options

ImmunityBio, Inc. Director Michael D. Blaszyk was granted 162,786 stock options with an exercise price of $2.84, vesting over approximately one year.

Summary

• Michael D. Blaszyk, a Director of ImmunityBio, Inc. (IBRX), was granted 162,786 stock options.
• The stock options have an exercise price of $2.84 per share.
• The grant date for these options was June 18, 2025.
• One hundred percent (100%) of the shares subject to the award will vest on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Mr. Blaszyk's continued service as a Service Provider, as defined in the Issuer's 2025 Equity Incentive Plan.
• The options have an expiration date of June 18, 2035.
• Following this transaction, Mr. Blaszyk directly beneficially owns 162,786 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's performance through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• The options are granted at a specific exercise price, providing a clear benchmark for future value creation.

Negatives

• No explicit negatives are detailed in this Form 4 filing, which primarily reports insider transactions.

Risks

• The value of the stock options is subject to the future market price of ImmunityBio, Inc. common stock, meaning the options may not be 'in the money' if the stock price does not exceed the exercise price.
• Vesting is conditional on continued service, meaning the options could be forfeited if the director's service terminates before the vesting date.

Future Outlook

The stock options are subject to a future vesting schedule, with 100% of the award vesting on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders, provided the director continues to serve as a Service Provider.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including biotechnology, to align management and board interests with shareholder returns.
• The vesting schedule, contingent on continued service, is typical for equity awards designed to promote retention and long-term commitment.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar size and stage within the biotechnology sector, though no specific comparable companies or projects are detailed in this filing.

Corporate Governance

Related Party Transactions

• The grant of stock options to Michael D. Blaszyk, a Director of ImmunityBio, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options could lead to potential future dilution if exercised, but also aligns the director's incentives with increasing shareholder value.
• Director (Michael D. Blaszyk): Receives equity-based compensation, incentivizing long-term commitment and performance tied to the company's stock price.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

ImmunityBio, IBRX, Form 4, Stock Option, Director Compensation, Insider Transaction, Equity Incentive Plan, Vesting